Patents by Inventor Ssucheng Jeff Hsu

Ssucheng Jeff Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATIONS FOR THE TREATMENT OF CANCER
    Publication number: 20230301979
    Abstract: The present invention relates to combinations comprising a checkpoint inhibitor and a c-Met inhibitor, Compound 1. The invention also relates to crystalline forms of the free base of Compound 1, as well as crystalline forms of salts of Compound 1, in combination with a checkpoint inhibitor. The invention also relates to pharmaceutical compositions comprising these combinations. The invention further relates to methods of treating cancer by administering Compound 1 as a single agent or a combination described herein.
    Type: Application
    Filed: July 29, 2021
    Publication date: September 28, 2023
    Inventors: Gisela Schwab, Christian Scheffold, Colin Chong, Ssucheng Jeff Hsu, Peter Lamb, Peiwen Yu
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 11633500
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: April 25, 2023
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20210145979
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: April 17, 2020
    Publication date: May 20, 2021
    Applicant: AGENSYS, INC.
    Inventors: Daniel Sousa PEREIRA, Faisal Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 10646583
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: May 12, 2020
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20180236096
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 23, 2018
    Inventors: Daniel Sousa PEREIRA, Faisal Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • Antibody drug conjugates (ADC) that bind to CD37 proteins
    Patent number: 9925273
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Grant
    Filed: July 30, 2014
    Date of Patent: March 27, 2018
    Assignee: AGENSYS, INC.
    Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
  • ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO CD37 PROTEINS
    Publication number: 20160051694
    Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.
    Type: Application
    Filed: July 30, 2014
    Publication date: February 25, 2016
    Inventors: Daniel Sousa PEREIRA, Faisil Hayat MALIK, Josh SNYDER, Leslie Renee BUTTERWORTH, Ssucheng Jeff HSU, Peng YANG, Claudia Isabel GUEVARA
  • Antagonist antibodies against EPHB3
    Patent number: 8377439
    Abstract: EphB3-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating an EphB3-related disease or disorder.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: February 19, 2013
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Ssucheng Jeff Hsu, Linda Masat